Nivolumab Versus Gemcitabine or Pegylated Liposomal Doxorubicin for Patients With Platinum-Resistant Ovarian Cancer: Open-Label, Randomized Trial in Japan (NINJA).
Junzo HamanishiNobuhiro TakeshimaNoriyuki KatsumataKimio UshijimaTadashi KimuraSatoshi TakeuchiKoji MatsumotoKimihiko ItoMasaki MandaiHidekatsu NakaiSakuragi NoriakiHidemichi WatariNobutaka TakahashiHidenori KatoKosei HasegawaKan YonemoriMika MizunoKazuhiro TakeharaHitoshi NiikuraTakashi SawasakiSari NakaoToshiaki SaitoTakayuki EnomotoSatoru NagaseNao SuzukiTakashi MatsumotoAsumi OkumuraKenzo SonodaSatomi AiharaYoichi AokiAikou OkamotoHirokuni TakanoHiroshi KobayashiHisamori KatoYoshito TeraiAkira TakazawaYusuke TakahashiYoshinobu NambaDaisuke AokiKeiichi FujiwaraToru SugiyamaIkuo KonishiPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)
Although well-tolerated, nivolumab did not improve OS and showed worse PFS compared with GEM or PLD in patients with platinum-resistant ovarian cancer.